Media store

Media Releases

Published on: 11 November 2019

Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone

Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis.1 The study met the primary ...

Published on: 11 November 2019

Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy

Roche today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA).

Published on: 6 November 2019

Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting

Roche today announced new data for its approved and investigational medicines across a range of blood diseases will be presented at the 61st American Society of Hematology (ASH) Annual Meeting from 7 ...

Upcoming Events

All

17March

Annual General Meeting (tentative)

(CEST)

Basel, Switzerland

add to calendar

22April

First quarter sales 2020

(CEST)

Basel

23July

Half year results 2020

(CEST)

Basel

16October

Third quarter sales 2020

(GMT)

Basel

Topics

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11